Vimarsana
Biggest News Aggregation in the World

Page 28 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene to Present at Upcoming Investor Conferences - Vimarsana News

BeiGene to Present at Upcoming Investor Conferences

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The 6th Annual Cowen IO

BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma - Vimarsana News

BeiGene Receives European Commission Approval for BRUKINSA (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma

BRUKINSA is the first and only Bruton's Tyrosine Kinase (BTK) inhibitor for marginal zone lymphoma approved in the European Union BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America - Vimarsana News

BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America

BRUKINSA received Marketing Authorization as a treatment for rare blood cancers in six countries in Central and South America BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology

BeiGene Receives Positive CHMP Opinion for BRUKINSA (zanubrutinib) for the Treatment of Adults With CLL - Vimarsana News

BeiGene Receives Positive CHMP Opinion for BRUKINSA (zanubrutinib) for the Treatment of Adults With CLL

14.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee ... Seite 1

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA (zanubrutinib) Compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial - Vimarsana News

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA (zanubrutinib) Compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial

12.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that BRUKINSA ... Seite 1

Related Topics:
New Drug Application